NasdaqGS - Nasdaq Real Time Price USD
Bio-Techne Corporation (TECH)
As of 11:20 AM EDT. Market Open.
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
1,159,060.00
1,159,060.00
1,136,702.00
1,105,599.00
931,032.00
--
Cost of Revenue
389,335.00
389,335.00
366,887.00
349,103.00
298,182.00
--
Gross Profit
769,725.00
769,725.00
769,815.00
756,496.00
632,850.00
--
Operating Expense
526,830.00
526,830.00
478,817.00
460,668.00
390,160.00
--
Operating Income
242,895.00
242,895.00
290,998.00
295,828.00
242,690.00
--
Net Non Operating Interest Income Expense
-12,413.00
-12,413.00
-7,805.00
-10,515.00
-13,479.00
--
Other Income Expense
-44,793.00
-44,793.00
55,466.00
16,073.00
-81,036.00
--
Pretax Income
185,689.00
185,689.00
338,659.00
301,386.00
148,175.00
--
Tax Provision
17,584.00
17,584.00
53,217.00
38,287.00
8,590.00
--
Net Income Common Stockholders
168,072.00
168,072.00
285,193.00
271,930.00
140,324.00
--
Diluted NI Available to Com Stockholders
168,072.00
168,072.00
285,193.00
271,930.00
140,324.00
--
Basic EPS
1.07
--
1.81
1.73
0.91
1.50
Diluted EPS
1.05
--
1.76
1.66
0.87
1.46
Basic Average Shares
157,708.00
--
157,179.00
156,876.00
154,988.00
152,804.00
Diluted Average Shares
160,774.00
--
161,855.00
164,116.00
161,932.00
157,604.00
Total Operating Income as Reported
206,686.00
206,686.00
298,944.00
296,590.00
237,296.00
--
Total Expenses
916,165.00
916,165.00
845,704.00
809,771.00
688,342.00
--
Net Income from Continuing & Discontinued Operation
168,105.00
168,105.00
285,263.00
272,051.00
140,410.00
--
Normalized Income
202,750.21
202,750.21
237,936.98
259,294.72
217,593.71
--
Interest Income
3,323.00
3,323.00
3,410.00
794.00
473.00
--
Interest Expense
15,736.00
15,736.00
11,215.00
11,309.00
13,952.00
--
Net Interest Income
-12,413.00
-12,413.00
-7,805.00
-10,515.00
-13,479.00
--
EBIT
201,425.00
201,425.00
349,874.00
312,695.00
162,127.00
--
EBITDA
313,136.00
313,136.00
457,112.00
413,764.00
249,874.00
--
Reconciled Cost of Revenue
309,334.00
309,334.00
291,725.00
280,526.00
238,223.00
--
Reconciled Depreciation
111,711.00
111,711.00
107,238.00
101,069.00
87,747.00
--
Net Income from Continuing Operation Net Minority Interest
168,105.00
168,105.00
285,263.00
272,051.00
140,410.00
--
Total Unusual Items Excluding Goodwill
-38,282.00
-38,282.00
56,140.00
14,612.00
-81,936.00
--
Total Unusual Items
-38,282.00
-38,282.00
56,140.00
14,612.00
-81,936.00
--
Normalized EBITDA
351,418.00
351,418.00
400,972.00
399,152.00
331,810.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-3,636.79
-3,636.79
8,813.98
1,855.72
-4,752.29
--
6/30/2020 - 2/9/1989
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
UTHR United Therapeutics Corporation
369.56
+2.78%
RARE Ultragenyx Pharmaceutical Inc.
56.85
-0.47%
INCY Incyte Corporation
66.38
+0.14%
PCVX Vaxcyte, Inc.
116.54
+0.91%
RPRX Royalty Pharma plc
28.11
+0.95%
MRVI Maravai LifeSciences Holdings, Inc.
8.18
-1.33%
FTRE Fortrea Holdings Inc.
19.00
+0.16%
IONS Ionis Pharmaceuticals, Inc.
38.73
+2.34%
JAZZ Jazz Pharmaceuticals plc
117.12
-0.14%
ROIV Roivant Sciences Ltd.
12.04
+1.30%